Abstract
Transcatheter aortic valve replacement (TAVR) is an alternative therapeutic intervention to surgical aortic valve replacement (SAVR) for patients with severe aortic stenosis (AS).1 With the broadening of indications for TAVR to include younger and lower-risk patients, the long-term durability of transcatheter heart valves (THVs) has become relevant. For TAVR in native AS, the incidence of THV deterioration requiring SAVR or TAVR-in-TAVR is low2,3; however, the long-term durability and outcomes of THV after valve-in-valve (ViV) TAVR for degenerated SAVR is less well defined.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
